210 related articles for article (PubMed ID: 35139729)
1. Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.
Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
Acta Oncol; 2022 Apr; 61(4):523-530. PubMed ID: 35139729
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
3. New Insights into Adjuvant Therapy for Localized Colon Cancer.
González NS; Ros Montaña FJ; Illescas DG; Argota IB; Ballabrera FS; Élez Fernández ME
Hematol Oncol Clin North Am; 2022 Jun; 36(3):507-520. PubMed ID: 35577707
[TBL] [Abstract][Full Text] [Related]
4. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Tie J; Cohen JD; Lahouel K; Lo SN; Wang Y; Kosmider S; Wong R; Shapiro J; Lee M; Harris S; Khattak A; Burge M; Harris M; Lynam J; Nott L; Day F; Hayes T; McLachlan SA; Lee B; Ptak J; Silliman N; Dobbyn L; Popoli M; Hruban R; Lennon AM; Papadopoulos N; Kinzler KW; Vogelstein B; Tomasetti C; Gibbs P;
N Engl J Med; 2022 Jun; 386(24):2261-2272. PubMed ID: 35657320
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
7. Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials.
Conca V; Ciracì P; Boccaccio C; Minelli A; Antoniotti C; Cremolini C
Cancer Treat Rev; 2024 May; 126():102735. PubMed ID: 38613871
[TBL] [Abstract][Full Text] [Related]
8. Circulating DNA in the neoadjuvant setting of early stage colon cancer.
Bregni G; Pretta A; Senti C; Acedo Reina E; Vandeputte C; Trevisi E; Gkolfakis P; Kehagias P; Deleporte A; Van Laethem JL; Vergauwe P; Van den Eynde M; Deboever G; Janssens J; Demolin G; Holbrechts S; Clausse M; De Grez T; Peeters M; D'Hondt L; Geboes K; Besse-Hammer T; Rothé F; Flamen P; Hendlisz A; Sclafani F
Acta Oncol; 2022 Oct; 61(10):1223-1229. PubMed ID: 35866544
[TBL] [Abstract][Full Text] [Related]
9. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer.
Akagündüz B; Guven DC; Ozer M; Okten IN; Atag E; Unek İT; Tatli AM; Karaoglu A
J Geriatr Oncol; 2023 Mar; 14(2):101367. PubMed ID: 36038467
[No Abstract] [Full Text] [Related]
10. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
[TBL] [Abstract][Full Text] [Related]
11. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
12. Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?
Morris VK; George TJ
Clin Cancer Res; 2022 Feb; 28(3):438-440. PubMed ID: 34848532
[TBL] [Abstract][Full Text] [Related]
13. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
[TBL] [Abstract][Full Text] [Related]
14. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
Bent A; Raghavan S; Dasari A; Kopetz S
Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
[TBL] [Abstract][Full Text] [Related]
16. ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis.
Yekedüz E; Köksoy EB; Akbulut H; Ürün Y; Utkan G
Future Oncol; 2021 Jan; 17(3):349-357. PubMed ID: 33356539
[No Abstract] [Full Text] [Related]
17. The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review.
Chakrabarti S; Xie H; Urrutia R; Mahipal A
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003583
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
19. Serial Circulating Tumor DNA in Monitoring the Effect of Neoadjuvant and Adjuvant Immunotherapy in Patients With Colon Cancer: Case Series and Review of the Literature.
Qin Q; Yang K; Ma T; Wang H; Yu P; Yuan M; Chen Y; Wang H
J Immunother; 2022 Oct; 45(8):358-362. PubMed ID: 35980372
[TBL] [Abstract][Full Text] [Related]
20. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans.
Li Y; Heer AK; Sloane HS; Edelstein DL; Tie J; Gibbs P; Barzi A
JAMA Health Forum; 2024 May; 5(5):e241270. PubMed ID: 38819797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
